CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value of over $551 million as of Q4 2025.

The gene-editing company remains on analysts’ radar and currently carries a Moderate Buy rating, with an average share price upside of 17% as of March 4.

Recent updates include Truist Financial analyst Joon Lee reiterating the firm’s Buy rating on the stock on March 2, according to TipRanks.

Earlier on February 17, Chardan Capital lifted its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $76 from $74 and maintained a Buy rating. The adjustment followed the company’s business update and the announcement of its fourth-quarter results on February 12.

According to TipRanks, Chardan analyst Geulah Livshits highlighted the momentum in the company’s siRNA therapies and vivo cardiovascular editing, along with progress across multiple clinical and preclinical programs.

Following the Q4 report, TD Cowen also lifted the price target to $45 from $40 with a Hold rating. The firm noted strong momentum in CASGEVY, with quarterly revenue of $54 million and full-year revenue of $116 million. Moreover, analyst Tyler Van Buren said he was keenly anticipating several clinical updates that are scheduled for the second half of 2026.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company focused on developing CRISPR/Cas9-based therapeutics to treat genetically-defined diseases and engineer advanced cellular therapies.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Magic Formula Stocks for 2026.

Disclosure: None. Follow Insider Monkey on Google News.